JNJ Johnson & Johnson

137.52
-1  -1%
Previous Close 138.52
Open 139.35
Price To Book 6.13
Market Cap 366184422080
Shares 2,662,772,121
Volume 10,485,289
Short Ratio 1.83
Av. Daily Volume 6,314,638

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Phase 3 discontinuation announced October 17, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Approval announced February 14, 2018.
Apalutamide
Non-metastatic castration-resistant prostate cancer (CRPC)
FDA Approval announced July 17, 2018.
D/C/F/TAF
HIV
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approval announced October 30, 2017. sNDA flled December 14, 2018.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
FDA Approval announced October 30, 2018.
INVOKANA CANVAS
Type 2 diabetes
sNDA filing announced March 28, 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Approval announced May 7, 2018.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
FDA approval announced March 5, 2019.
Esketamine
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced October 13, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approval announced October 20, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approval announced October 20, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approval announced July 13, 2017.
Guselkumab
Plaque psoriasis
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Sirukumab
Rheumatoid arthritis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
sNDA approval announced February 8, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
FDA Approval announced April 12, 2019.
Erdafitinib
Urothelial cancer
Announced May 18, 2018 that dosing will be stopped.
Atabecestat
Alzheimer’s disease
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
sBLA filing announced March 12, 2019.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Phase 3 primary endpoint met - December 12, 2019.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 2a initiation announced January 17, 2019.
Guselkumab
Ulcerative colitis
sBLA filed December 20, 2018.
STELARA (USTEKINUMAB)
Ulcerative colitis
Phase 3 data met co-primary endpoints - January 30, 2019.
Apalutamide
Metastatic castration-sensitive prostate cancer (mCSPC).
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer
Approval announced February 27, 2019.
Guselkumab
Plaque psoriasis
sNDA filing announced March 26, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)

Latest News

  1. The Top 10 Biotechnology Companies (JNJ, ROG.VX)
  2. Be Careful With Healthcare Stocks Here
  3. Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion
  4. Here Are the Key Takeaways From J&J's Q1 Earnings Report
  5. Idorsia confirms 2019 spending plan as clinical trials "on track"
  6. Edited Transcript of JNJ earnings conference call or presentation 16-Apr-19 12:30pm GMT
  7. Liability Issues Weigh on Johnson & Johnson
  8. Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative
  9. Stock Market News For Apr 17, 2019
  10. StockBeat - UnitedHealth Deepens Losses as Fears Over Political Risk Rise
  11. 10 Best Stocks to Buy and Hold Forever
  12. Is More Downside Ahead for Boeing Stock? Should You Buy?
  13. Dow stock that's lost $34 billion in market cap in the last week could be a buy, says investor
  14. 5 takeaways from Johnson & Johnson’s first-quarter results
  15. Why The Rally In Johnson & Johnson Stock May Top Out At $150
  16. Solid Drug Sales, Cost Control Boost Johnson & Johnson
  17. Why ‘Scared’ Investors May Push Health Care Stocks Even Lower
  18. Asian shares edge lower despite encouraging China GDP data
  19. US halts sales of pelvic mesh tied to injuries in women
  20. Johnson & Johnson and United Healthcare Face a Series of Obstacles